Press Releases

InVivo Therapeutics Announces Seventh Patient Conversion in The INSPIRE Study of the Neuro-Spinal Scaffold

Published: March 28, 2017

– Patient Converts from Complete to Incomplete Spinal Cord Injury with Sensory and Motor Improvements – CAMBRIDGE, Mass. (Mar 28, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the patient enrolled in January in the INSPIRE study of the Neuro-Spinal Scaffold has improved from a complete AIS A spinal cord injury (SCI) to an incomplete AIS B SCI in the time between the one-month and the two-month evaluations. This is the seventh out of the 11 patients (63.6% conversion rate) with at least one month of follow-up to have had an AIS grade improvement. Two additional patients are early […]

View Article
InVivo Therapeutics to Present at Needham and Company’s 16th Annual Healthcare Conference

Published: March 27, 2017

CAMBRIDGE, Mass. (Mar 27, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin, Chief Executive Officer and Chairman, will present at the Needham and Company’s 16th Annual Healthcare Conference on Wednesday, April 5, 2017 at 1:40 PM Eastern Time at the Westin NY Grand Central Hotel in New York, NY. This is the first time that the company has been invited to present at the Needham and Company Annual Healthcare Conference. During his presentation, Mr. Perrin will highlight the recent progress of the company’s Neuro-Spinal Scaffold™ program, and provide an overview of the company. A live webcast […]

View Article
InVivo to Initiate Cervical Spinal Cord Injury Study

Published: March 23, 2017

– Company Receives Investigational Testing Authorization from Health Canada to Conduct Cervical Spinal Cord Injury Study – CAMBRIDGE, Mass. (Mar 23, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Health Canada has approved the company’s Investigational Testing Authorization application to commence a clinical study of the Neuro-Spinal Scaffold™ in patients with acute, complete (AIS A) cervical (C5-T1) spinal cord injuries (SCIs). InVivo currently is in late stage conversation with several site Research Ethics Boards and expects to announce its first Canadian site in the coming weeks. “This approval is an important step towards our goal of redefining the […]

View Article
InVivo Therapeutics Announces Submission to the FDA of Its Nonclinical Studies Module for the Neuro-Spinal Scaffold

Published: March 21, 2017

– First of Three Modules to be Submitted for Product Approval – CAMBRIDGE, Mass. (Mar 21, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that it has submitted its first module containing nonclinical studies to the U.S. Food and Drug Administration (FDA) as part of its Humanitarian Device Exemption (HDE) modular submission and review process for the Neuro-Spinal Scaffold. InVivo’s modular HDE process is based on a submission of three modules to the FDA that constitute a complete HDE submission once all have been submitted: a nonclinical studies module, a manufacturing module, and a clinical data module. This process allows […]

View Article
InVivo Therapeutics Announces Enrollment of New Patient into the INSPIRE Study at New Jersey’s Cooper Neurological Institute

Published: March 20, 2017

CAMBRIDGE, Mass. (Mar 20, 2017)– InVivo Therapeutics Holdings Corp. (NVIV) today announced that a new patient has been enrolled into The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury at the Cooper Neurological Institute (CNI), which is part of Cooper University Hospital, a network providing care to Southern New Jersey and the Delaware Valley. Steven Yocom, DO, Assistant Professor of Neurosurgery, Director of the CNI Spine Program and Principal Investigator at this site, performed the implantation approximately 29 hours after the injury […]

View Article
InVivo Therapeutics Receives Clinical Trial Application Approval from UK’s Medicines Healthcare Products Regulatory Agency

Published: March 15, 2017

– INSPIRE Study Expanding to United Kingdom – CAMBRIDGE, Mass. (Mar 15, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the Medicines Healthcare Products Regulatory Agency (MHRA) has approved the company’s Clinical Trial Authorization Application to commence clinical studies in the United Kingdom (UK). The approval will allow the company to enroll patients from the UK into the ongoing INSPIRE study once InVivo receives a favorable opinion from a Research Ethics Committee (REC), Health Regulatory Approval (HRA), and a site is open for enrollment. InVivo currently is in late-stage conversation with various clinical sites, and its first UK site […]

View Article
InVivo Therapeutics Reports 2016 Year-end Financial Results and Business Update

Published: March 10, 2017

CAMBRIDGE, Mass. (March 10, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the year ended December 31, 2016. Mark Perrin, InVivo’s CEO and Chairman, said, “2016 was a year marked by meaningful and significant progress. In 2016, we: received approval for converting the Neuro-Spinal Scaffold™ pilot study to the pivotal INSPIRE study; received approval to initiate the INSPIRE study in Canada (1st global step for InVivo); added 13 new clinical sites, including our first ex-U.S. sites (both in Canada); enrolled seven new patients, with three of those patients achieving the primary endpoint of conversion to partial […]

View Article
InVivo Therapeutics Announces Enrollment of New Patient into the INSPIRE Study at Keck Hospital, University of Southern California

Published: March 9, 2017

CAMBRIDGE, Mass. (Mar 9, 2017)– InVivo Therapeutics Holdings Corp. (NVIV) today announced that a new patient has been enrolled into The INSPIRE Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury) at the Keck Hospital of University of Southern California (USC). Patrick Hsieh, M.D., Principal Investigator at this site, performed the implantation approximately 82 hours after the injury occurred. “The implantation of the Neuro-Spinal Scaffold  went smoothly and the patient is recovering well,” Dr. Hsieh said. “I have now implanted two patients, and it […]

View Article
InVivo Therapeutics to Present and Exhibit at Spine Summit 2017

Published: February 28, 2017

-Oral Presentations by Dom Coric, M.D. and Michael Fehlings, M.D., Ph.D.- -What’s New Session by Michael Fehlings, M.D., Ph.D.- CAMBRIDGE, Mass. (Feb 28, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that two INSPIRE study Principal Investigators, Dom Coric, M.D. and Michael Fehlings, M.D., Ph.D., will be giving oral presentations at the Spine Summit 2017 to be held March 8-11, 2017 in Las Vegas, NV. Dr. Coric will present “INSPIRE Study Update on 10 Subjects Implanted with a Bioresorbable Polymer Scaffold Following Acute Complete Thoracic Spinal Cord Injury,” and Dr. Fehlings will present “Magnetic Resonance Imaging (MRI) Does Not […]

View Article
InVivo Therapeutics to Present at Cowen and Company 37th Annual Health Care Conference

Published: February 27, 2017

CAMBRIDGE, Mass. (Feb 27, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin, Chief Executive Officer and Chairman, will present at the Cowen and Company 37th Annual Health Care Conference on Monday, March 6, 2017 at 2:00 P.M. Eastern Time at the Boston Marriott Copley Place in Boston, MA. Mr. Perrin will highlight the recent progress of the Company’s Neuro-Spinal Scaffold™ program, and provide an overview of the company. A live webcast will be available at http://wsw.com/webcast/cowen38/nviv and a webcast replay will be available at the same address approximately one hour after the live webcast presentation. Please […]

View Article

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on the InVivo website for historical purposes only. InVivo assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.